The effectiveness and safety of preoperative use of erythropoietin in patients scheduled for total hip or knee arthroplasty

Medicine (United States)

Volumn 95, Issue 27, 2016, Pages

  Zhao, Yan ^a   Jiang, Chao ^a   Peng, Huiming ^a   Feng, Bin ^a   Li, Yulong ^a   Weng, Xisheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

allogeneic transfusion; erythropoietin; hemoglobin; total hip arthroplasty; total knee arthroplasty

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; EPO PROTEIN, HUMAN;

ARTICLE; BLOOD TRANSFUSION; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEMOGLOBIN DETERMINATION; HIP ARTHROPLASTY; HUMAN; LUNG EMBOLISM; META ANALYSIS; OSTEOARTHRITIS; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIORITY JOURNAL; RETICULOCYTE COUNT; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TOTAL KNEE ARTHROPLASTY; COST BENEFIT ANALYSIS; ECONOMICS; HIP REPLACEMENT; KNEE REPLACEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UTILIZATION;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; ERYTHROPOIETIN; HUMANS; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85013727058     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004122     Document Type: Article

References (47)

1. Sizer SC, Cherian JJ, Elmallah RD, et al. Predicting blood loss in total knee and hip arthroplasty. Orthoped Clin North Am 2015;46:445-59
2. Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010;50: 2080-99
3. Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999;81:2-10
4. Blajchman MA. Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. Vox sanguinis 1998;74 (suppl 2):315-9
5. Blajchman MA, Bordin JO. Mechanisms of transfusion-associated immunosuppression. Curr Opin Hematol 1994;1:457-61
6. Kopolovic I, Ostro J, Tsubota H, et al. A systematic review of transfusion-associated graft-versus-host disease. Blood 2015;126: 406-14
7. McGonagle L, Murnaghan JJ. Blood management strategies in lower limb arthroplasty. Orthopaed Trauma 2015;29:189-94
8. Xie J, Feng X, Ma J, et al. Is postoperative cell salvage necessary in total hip or knee replacement? A meta-analysis of randomized controlled trials. Int J Surg 2015;21:135-44
9. Jakovina Blazekovic S, Bicanic G, Hrabac P, et al. Pre-operative autologous blood donation versus no blood donation in total knee arthroplasty: a prospective randomised trial. Int Orthop 2014;38:341-6
10. Kelly MP, Zebala LP, Kim HJ, et al. Effectiveness of preoperative autologous blood donation for protection against allogeneic blood exposure in adult spinal deformity surgeries: a propensity-matched cohort analysis. J Neurosurg Spine 2015;24:1-7
11. Na HS, Shin SY, Hwang JY, et al. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion 2011;51:118-24
12. Buljan M, Nemet D, Golubic-Cepulic B, et al. Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. Int Orthopaed (SICOT) 2012;36:703-9
13. So-Osman C, Nelissen RG, Koopman-Gemert AW, et al. Patient blood management in elective total hip-and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology 2014;120:839-51
14. Bedair H, Yang J, Dwyer MK, et al. Preoperative erythropoietin alpha reduces postoperative transfusions in THAand TKA but may not be costeffective. Clin Orthopaed Relat Res 2015;473:590-6
15. Fergusson DA, Hebert P. The health(y) cost of erythropoietin in orthopedic surgery. Canad J Anaesth 2005;52:347-51
16. Alsaleh K, Alotaibi GS, Almodaimegh HS, et al. The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: a meta-analysis of randomized clinical trials. J Arthroplasty 2013;28:1463-72
17. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 2011;343:d5928
18. Carneiro IA, Drakeley CJ, Owusu-Agyei S, et al. Haemoglobin and haematocrit: is the threefold conversion valid for assessing anaemia in malaria-endemic settings? Malaria J 2007;6:67
19. Review Manager (RevMan) [Computer, program]., Version, 5.3., Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration 2014
20. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-hand book.org
21. Lofthouse RA, Boitano MA, Davis JR, et al. Preoperative administration of epoetin alfa to reduce transfusion requirements in elderly patients having primary total hip or knee reconstruction. J South Orthop Assoc 2000;9:175-81
22. Lee GC, Pagnano MW, Jacofsky DJ, et al. Use of erythropoietin in twostage reimplantation total hip arthroplasty. Clin Orthop Relat Res 2003;49-54
23. Weber EW, Slappendel R, Hemon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005;22:249-57
24. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000;133: 845-54
25. Gombotz H, Gries M, Sipurzynski S, et al. Preoperative treatment with recombinant human erythropoietin or predeposit of autologous blood in women undergoing primary hip replacement. Acta Anaesth Scand 2000;44:737-42
26. Aksoy MC, Tokgozoglu AM. Erythropoietin for autologous blood donation in total hip arthroplasty patients. Arch Orthop Trauma Surg 2001;121:162-5
27. Matsuda S, Kondo M, Mashima T, et al. Recombinant human erythropoietin therapy for autologous blood donation in rheumatoid arthritis patients undergoing total hip or knee arthroplasty. Orthopedics 2001;24:41-4
28. Olijhoek G, Megens JG, Musto P, et al. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 2001;41:957-63
29. Avall A, Hyllner M, Bengtson JP, et al. Recombinant human erythropoietin in preoperative autologous blood donation did not influence the haemoglobin recovery after surgery. Acta anaesth Scand 2003;47:687-92
30. Bezwada HP, Nazarian DG, Henry DH, et al. Preoperative use of recombinant human erythropoietin before total joint arthroplasty. J Bone Joint Surg Am 2003;85:1795-800
31. Hardwick ME, Morris BM, Colwell CW Jr. Two-dose epoetin alfa reduces blood transfusions compared with autologous donation. Clin Orthop Relat Res 2004;240
32. Rosencher N, Poisson D, Albi A, et al. Two injections of erythropoietin correct moderate anemia in most patients awaiting orthopedic surgery. Canad J Anaesth 2005;52;160-165
33. Deutsch A, Spaulding J, Marcus RE. Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty. J Arthroplasty 2006;21:628-35
34. Keating EM, Callaghan JJ, Ranawat AS, et al. A randomized, parallelgroup, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty: effect on postoperative vigor and handgrip strength. J Arthroplasty 2007;22:325-33
35. Moonen AF, Thomassen BJ, Knoors NT, et al. Pre-operative injections of epoetin-alpha versus post-operative retransfusion of autologous shed blood in total hip and knee replacement: a prospective randomised clinical trial. J Bone Joint Surg Br 2008;90:1079-83
36. Sambandam B, Batra S, Gupta R, et al. Blood conservation strategies in orthopedic surgeries: a review. J Clin Orthop Trauma 2013;4: 164-70
37. Krzyzanski W, Jusko WJ, Wacholtz MC, et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 2005;26:295-306
38. Ramakrishnan R, Cheung WK, Wacholtz MC, et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004;44:991-1002
39. Sehat KR, Evans RL, Newman JH. Hidden blood loss following hip and knee arthroplasty. Correct management of blood loss should take hidden loss into account. J Bone Joint Surg Br 86D 2004:561-5
40. Pattison E, Protheroe K, Pringle RM, et al. Reduction in haemoglobin after knee joint surgery. Ann Rheum Dis 1973;32:582-4
41. National Clinical Guideline C. National Institute for Health and Care Excellence: Clinical Guidelines. Blood Transfusion. London: National Institute for Health and Care Excellence (UK) Copyright (c) 2015 National Clinical Guideline Centre. 2015
42. Bose WJ. The potential use of human recombinant erythropoietin in orthopedic surgery. Orthopedics 1996;19:325-8
43. Nam D, Nunley RM, Johnson SR, et al. Thromboembolism prophylaxis in hip arthroplasty: routine and high risk patients. J Arthroplasty 2015;30:2299-303
44. Flierl MA, Messina MJ, Mitchell JJ, et al. Venous thromboembolism prophylaxis after total joint arthroplasty. Orthopedics 2015;38:252-63
45. Coyle D, Lee KM, Fergusson DA, et al. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med 1999;9:21-30
46. Green WS, Toy P, Bozic KJ. Cost minimization analysis of preoperative erythropoietin vs autologous and allogeneic blood donation in total joint arthroplasty. J Arthroplasty 2010;25:93-6
47. Degener F, Postma MJ. A systematic literature review of the costeffectiveness of erythropoietin in orthopedic surgery: there is a need for differentiation between total hip and knee arthroplasty. Value in Health 2015;18:A160